Health
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia – Wiley
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations,…
Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel beta coronavirus, has led to unprecedented healthcare challenges on a global scale. Development of anti-viral immunity is key to reducing spread of infection and gaining pandemic control. Impressive collaborative efforts have led to the rapid development of multiple efficacious vaccines against SARS-CoV-2. BNT162b2 is a nucleoside-modified mRNA that encodes a full-length Spike that is stabilised in the pre-fusion…
-
General13 hours agoChina and Philippines trade blame over latest South China Sea clash
-
General20 hours agoCalls for government to ‘get on with’ CSIRO Ginninderra Experiment Station land sale after three-year delay
-
Noosa News24 hours agoIs Auckland New Zealand’s New Cultural Capital?
-
Noosa News22 hours agoBetty’s Burgers National Burger Day